Skip to Main Content

Acquired pure RBC aplasia is rare. It is an autoimmune disease mediated by T lymphocytes or by an IgG antibody against erythroid precursors in the bone marrow or both. In adults, the disease is usually idiopathic. However, cases have been seen in association with SLE, chronic lymphocytic leukemia (CLL), lymphomas, or thymoma. Some medications (phenytoin, chloramphenicol) may cause RBC aplasia. Rarely, anti-erythropoietin antibodies cause pure RBC aplasia in patients who are treated with recombinant erythropoietin. Transient episodes of RBC aplasia are probably common in response to viral infections, especially parvovirus infections. However, these acute episodes will go unrecognized unless the patient has a chronic hemolytic disorder or a chronic immunocompromised state, in which case the hematocrit may fall precipitously.

The only signs are those of anemia unless the patient has an associated autoimmune or lymphoproliferative disorder. The anemia is often severe and normochromic, with low or absent reticulocytes. RBC morphology is normal, and the myeloid and platelet lines are unaffected. The bone marrow is normocellular with markedly reduced or absent erythroid progenitors; all non-erythroid elements are present and normal. The bone marrow karyotype is normal on standard banding cytogenetics. In some cases, chest imaging studies will reveal a thymoma.

The disorder must be distinguished from aplastic anemia (in which the marrow is hypocellular and all cell lines are affected) and from myelodysplasia. This latter disorder is recognized by the presence of morphologic abnormalities that should not be present in pure RBC aplasia.

Possible offending medications should be stopped. Most patients will require RBC transfusion support. With thymoma, resection alone results in amelioration of anemia in a low proportion of cases (about 10%). High-dose intravenous immune globulin has produced responses in a small number of cases, mainly during parvovirus infections. For idiopathic cases, the treatment of choice is immunosuppressive therapy with a calcineurin inhibitor (ie, cyclosporine) with durable response rates of 65–87%. A calcineurin inhibitor is usually used in conjunction with surgical resection in cases of thymoma. Monotherapy with corticosteroids produce responses in 30–60% of cases, but relapses are common once corticosteroids are discontinued. Anti-CD20 monoclonal antibody (rituximab) is the treatment of choice in the setting of anti-erythropoietin antibodies. In patients with an associated lymphoproliferative disorder, treating the neoplasm should also treat the anemia.


All patients should be referred to a hematologist.

Pop-up div Successfully Displayed

This div only appears when the trigger link is hovered over. Otherwise it is hidden from view.